Coverage
-
March 23, 2022
A New Jersey federal judge ruled Wednesday that the U.S. Food and Drug Administration's rejection of a proposed warning from Merck means federal law preempts state law claims in multidistrict litigation that the company failed to warn consumers about certain fracture risks of its osteoporosis drug Fosamax.
4 other articles on this case.
View all »